New drug could make stem cell transplants safer for rare immune disorder
NCT ID NCT05907746
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether a new drug called Briquilimab can make stem cell transplants safer for people with GATA2 deficiency, a rare genetic condition that weakens the immune system and raises the risk of infections and blood cancers. The study involves 13 participants aged 6 to 70 who receive Briquilimab before a donor stem cell transplant to help their body accept the new cells. Researchers will check if the transplant is successful by 100 days and one year after the procedure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Briquilimab
What this could lead to
If successful, this could make stem cell transplants safer and more effective for people with GATA2 deficiency, potentially reducing serious side effects.
What could go wrong
This is a small, early-phase trial with only 13 participants. The approach may still carry significant risks, including graft failure or severe side effects from the transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GATA2 DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States